Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pharmacokinetics of a single oral dose of 5 mg
Apixaban in subjects with normal renal function and subjects with end stage renal disease
(ESRD) maintained with hemodialysis.